홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

클라불란산

Clavulanic Acid

HCID 5280980
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
58001-44-8
표준 SMILES
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
InChIKey
HZZVJAQRINQKSD-PBFISZAISA-N
분자식
C8H9NO5
평균 분자량
199.16 g/mol
단동위원소 질량
199.04807239

개요

Clavulanic acid is antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes. It has a role as an anxiolytic drug, an EC 3.5.2.6 (beta-lactamase) inhibitor, an antibacterial drug and a bacterial metabolite. It is a conjugate acid of a clavulanate.

이름 및 식별자

우선 이름
Clavulanic Acid
IUPAC
(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
현지명
클라불란산
영어명
Clavulanic acid
분자식
C8H9NO5
분자량
199.16

이름 및 동의어

CLAVULANIC ACID58001-44-8Acido clavulanicoAcide clavulaniqueClavulansaeureacidum clavulanicumAntibiotic MM 14151MM 14151(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acidSerdaxinBRL 14151BRL-14151
이름 더 보기
Clavulanate acid3008-bC06662MM-14151antibioticmm14151Clavulanate MonomerClavulanic acid USP/EP/BP
rx-10100Clavulanate, Sodium(Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acidCHEBI:4894723521W1S24DTXSID2022830BRL14151(2R,3Z,5R)-3-(2-HYDROXYETHYLIDENE)-7-OXO-4-OXA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID

데이터베이스 식별자

CAS
58001-44-8
PubChem CID
5280980
DTXSID
DTXSID2022830
ChEMBL
CHEMBL777

물성

구조 계산 물성

XLogP
-1.2
극성 표면적
87.1 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
5
회전 가능 결합 수
2
무거운 원자 수
14
형식 전하
0
복잡도
324

실험 및 물리화학적 성질

Drugs · 4건

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LogP-1.5
Solubility3.37e+02 g/L
Human DrugsPharmaceuticals
Animal DrugsPharmaceuticals -> UK Veterinary Medicines Directorate List
Melting Point · 2건

117.5-118

117.5 - 118 °C

Physical DescriptionSolid
Dissociation Constants2.7

물리화학적 성질

끓는 점
545.8 · 545.8±50.0 °C(Predicted)
밀도
1.65 · 1.65±0.1 g/cm3(Predicted)
저장 조건
4 °C, · 4°C, protect from light, stored under nitrogen

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

유해성 정보

Regulatory InformationClavulanic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

독성 정보

Adverse Effects · 1건

Clavulanic acid, when administered with amoxicillin, can cause some mild gastrointestinal adverse effects. These include vomiting, nausea, loose stools, and discomfort. Antibiotic-associated diarrhea due to amoxicillin-clavulanic acid treatment is the most common adverse effect. There is a higher incidence of diarrhea when clavulanic acid is added to amoxicillin compared to amoxicillin alone. Diarrhea is more common in those taking a high dose of the extended-release form of clavulanic acid and amoxicillin. Drug-induced pancreatitis from clavulanic acid and amoxicillin has occurred in a few cases.

Toxicity Summary · 1건

The toxicity of clavulanic acid alone is unknown. However, the toxic effects of amoxicillin/clavulanate have been reported. The most common toxic effect is an idiosyncratic drug-induced hepatic injury which leads to a mixed hepatocellular-cholestatic injury, and it is more common in older men. Amoxicillin-clavulanic acid is the most common cause of idiosyncratic drug-induced hepatic injury. Risk factors for hepatic injury include sex, cytochrome P450, and genetic polymorphisms. These risk factors should be examined before administering amoxicillin/clavulanate to reduce the risk of toxic and adverse effects. In addition to early diagnosis and discontinuation of the drug, N-acetylcysteine can be administered to minimize damage. Additionally, steroids can be given to decrease the time it takes to return hepatic enzymes and bilirubin levels to normal. Liver failure is also a rare but possible toxic effect of amoxicillin-clavulanic acid.

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302

화학 및 산업

약리 정보

Protein BindingThe plasma protein binding of amoxicillin is about 25%.
Pharmacodynamics · 1건

Clavulanic acid inactivates some beta-lactamase enzymes that are produced by bacteria, therefore preventing enzymatic destruction of amoxicillin. This helps to treat a variety of bacterial infections which would otherwise be resistant to antibiotics without the addition of clavulanic acid.

Mechanism of Action · 1건

Clavulanic acid contains a beta-lactam ring in its structure that binds in an irreversible fashion to beta-lactamases, preventing them from inactivating certain beta-lactam antibiotics, with efficacy in treating susceptible gram-positive and gram-negative infections.

Biological Half-LifeThe half-life of clavulanic acid is reported to be similar to amoxicillin, and last 45-90 minutes. A study of radiolabeled clavulanic acid administered to 4 healthy volunteers determined a half-life of 0.8 h.
Metabolism/Metabolites · 1건

Clavulanic acid is heavily metabolized to form the metabolites 2,5-dihydro-4-(2- hydroxyethyl)-5-oxo-1H-pyrrole-3-carboxylic acid and 1-amino-4-hydroxy-butan-2-one. The first metabolite was found to account for 15.6% of the dose while the second metabolite was reported to account for 8.8% of the dose in one pharmacokinetic study.

FDA Pharmacological Classification · 5건

23521W1S24

CLAVULANIC ACID

Established Pharmacologic Class [EPC] - beta Lactamase Inhibitor

Mechanisms of Action [MoA] - beta Lactamase Inhibitors

Clavulanic acid is a beta Lactamase Inhibitor. The mechanism of action of clavulanic acid is as a beta Lactamase Inhibitor.

MeSH Pharmacological ClassificationEndogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.
Absorption, Distribution and Excretion

관련 반응

68건
반응 기록 만들기
HRID 3626 반응식
HRID 3626반응물로
HRID 127153 반응식
HRID 127153반응물로
HRID 324260 반응식
HRID 324260생성물로
HRID 324261 반응식
HRID 324261생성물로
HRID 324262 반응식
HRID 324262생성물로
HRID 342856 반응식
HRID 342856반응물로
HRID 368551 반응식
HRID 368551반응물로
HRID 370438 반응식
HRID 370438생성물로
이전1 / 9 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
ChEBI
CHEBI:48947
UNII
23521W1S24
EC Number
261-069-2
Nikkaji
J14.640D
용해도
2 O · H2O : 50 mg/mL (251.05 mM; Need ultrasonic)
물리적 상태
Solid
산도 계수 (pKa)
3.68 · 3.68±0.20(Predicted)
색상
Off-white to light yellow
· 4건

Clavulanic acid, when taken orally, is well absorbed in the gastrointestinal tract. After administration of radiolabeled clavulanic acid to four human subjects, a minimum of 73% absorption and the average absolute bioavailability was calculated at 64%. The mean Cmax in a group of 8 healthy research volunteers was 2.098 ± 0.441 micrograms/ml in a pharmacokinetic study. The same study reported a mean Tmax of 1.042 ± 0.80 hours. Tmax is reported to be 40-120 minutes according to another pharmacokinetic study.

About 40 to 65% of the clavulanic acid is excreted as unchanged drug in urine during the first 6 hours following ingestion. The metabolites of clavulanic acid are found to be excreted in the urine and feces and as carbon dioxide in expired air. Clavulanate is cleared by both renal and non-renal processes. About 17% of radiolabeled dose of clavulanic acid was found to be exhaled in expired air and 8% of a dose was found to be excreted in the feces.

A study in 4 healthy volunteers administered a radiolabeled dose of clavulanic acid determined a volume of distribution of 12L.Clavulanic acid is distributed to various tissues and interstitial fluid. Clinically significant concentrations have been measured in the gallbladder, abdomen, skin, fat, and muscle tissues. Bile, pus, synovial and peritoneal fluids are also found to have therapeutic concentrations of clavulanic acid. Studies of animals have demonstrated that clavulanic crosses the placenta.

The clearance of clavulanic acid in a pharmacokinetic study of 4 healthy volunteers administered a radiolabeled dose of clavulanic acid was 0.21 l/min. Another resource indicates the average clearance of clavulanic acid is 12.20 liters/h/70 kg. Dose adjustments may be required in patients with renal failure.

용도 및 제조

UsesUse (kg) in Switzerland (2009): >2500
Use ClassificationPharmaceuticals
응용 분야 · 3건

개요Clavulanic acid is a mold product with only weak intrinsic antibacterial activity, but it is an excellent irreversible inhibitor of most β-lactamases. It is believed to acylate the active site serine by mimicking the normal substrate. Hydrolysis occurs with some β-lactamases, but in many cases, subsequent reactions occur that inhibit the enzyme irreversibly. This leads to its classification as a mechanism-based inhibitor (or so-called suicide substrate). The precise chemistry is not well understood, but when clavulanic acid is added to ampicillin and amoxicillin preparations, the potency against β-lactamase–producing strains is markedly enhanced.

용도beta-lactamase inhibitor

일반 설명Clavulanic acid was found in the culture broth of Streptomyces clavuligerus by Beecham Research Laboratories in 1976. It was the first β-lactamase inhibitor. This antibiotic shows weak antibacterial activity against grampositive and gram-negative organisms but strong inhibitory activity against the β-lactamase produced by ampicillin-resistant bacteria. Clavulanic acid is used orally in combination with amoxicillin and with ticarcillin by injection to enhance the activities of these antibiotics against resistant infections.

상·하류 제품 정보

상류 원료

말토덱스트린SOYBEAN MEAL덱스트린대두 FLOUR

하류 제품

클라불란산2-아미노-2,4,4-트리메틸펜탄염

추가 설명

정의ChEBI: Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.